

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 14, 2025

Company name: TAUNS Laboratories, Inc.  
Representative: Masaki Nonaka, President and CEO  
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)  
Contact person: Yoshio Uchiyama, Director and CFO  
Tel: +81-55-953-9590

## **TAUNS Laboratories, Inc. has Concluded a Capital and Business Alliance Agreement with ElectraDx, Inc., an Innovative POCT and OTC Medical Diagnostics Company.**

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President & CEO; Securities Code: 197A; hereinafter referred to as "TAUNS") and ElectraDx, Inc. (with main operating offices in Maxim Park, 2 Parklands Ave, Eurocentral Jct, Motherwell ML1 4WQ, Scotland; Ron Zwanziger, Chairman and Founder; hereinafter referred to as "ElectraDx") today announced that the two companies have entered into a Capital and Business Alliance to jointly develop and commercialize next-generation diagnostic solutions that bring laboratory-quality testing to both chronic conditions and acute diseases.

Under the agreement, TAUNS has made an investment into ElectraDx through the subscription of its Series B Preferred Shares and the two companies have signed a Research, Development, Manufacturing, and Distribution Collaboration Agreement. Through this partnership, TAUNS will hold exclusive commercialization rights for Japan.

### **1. Background of Alliance**

#### ElectraDx's Business Activities and Competitive Advantages

ElectraDx is a pioneering diagnostics company developing the first lab-accurate, connected point of care (POCT) and home testing platform. Its mission is to bring laboratory-level testing directly to communities and homes, enabling early diagnosis and intervention for chronic conditions and acute diseases to improve health outcomes and reduce healthcare costs.

Founded in 2023, ElectraDx's leadership team has decades of diagnostics innovation in point of care and consumer diagnostics, including the development and launch of the first electrochemical blood glucose monitors, digital pregnancy test and point of care molecular systems.

ElectraDx is pioneering a new era of point-of-care and at-home diagnostics with a next-generation electrochemical-based testing platform that combines speed, accuracy, and affordability, using proprietary microfluidic, protein, and nucleic acid detection technologies to deliver results in under ten minutes from a simple fingerstick or swab sample. Its intelligent, connected device integrates portability, room-temperature storage, and cloud connectivity for real-time, actionable insights. With ultra low-cost strip and instruments, a broad test menu, and laboratory-level performance, ElectraDx is making advanced healthcare testing simple, affordable, and accessible—anywhere.

The ElectraDx system enables rapid and simultaneous testing of multiple parameters using only a small sample volume. It can process whole blood specimens directly - without the need for pretreatment - offering unmatched convenience across a variety of settings, including physicians' offices, community testing centers, pharmacies, clinics and emergency medical care facilities.

Its versatility supports a broad range of diagnostics applications, from respiratory infections and sexually transmitted diseases to chronic conditions such as cardiovascular disease, diabetes, inflammation markers and others, making it an innovative diagnostic tool for modern healthcare settings.

## **Features of ElectraDx Technology**

# **ElectraDx**

The first lab-accurate point of care and home-use platform shifting testing from the lab and into every home

### **Easy to use**

Simple, convenient, rapid  
test results (<10 minutes)

### **Broad Test Menu**

Diverse platform offers  
various community and home  
tests for key health needs.

### **Connected**

Integrated healthcare data  
enhances medical decision-making.



### **Lab-Quality Performance**

Next-Gen electrochemical tech  
ensures precise lab performance

### **Ultra Low Cost**

Affordable: low-cost device,  
ultra low-cost strips.

### **Intelligent Strip**

Intelligent test strip with on-strip  
electronic assay controls.

Confidential Information © ElectraDx Inc. 2025

1

## **Why We Turned to ElectraDx?**

Under the corporate slogan of “Peace of mind through diagnostic technology,” TAUNS has developed a variety of in vitro diagnostic test kits that apply our various diagnostic technologies and distributed them globally since its establishment in 1987.

By collaborating with ElectraDx, we intend to strengthen our position in the point-of-care testing respiratory infection market in Japan. We also aim to accelerate our entry into new disease areas, such as sexually transmitted infections and chronic diseases, by introducing innovative POCT solutions.

## **Comments from both presidents**

### **Comments from Masaki Nonaka, President and CEO, TAUNS Laboratories, Inc.**

We are very pleased to form this capital and business alliance with ElectraDx. This alliance will further accelerate the 'evolution and expansion of POCT', which is one of the key initiatives outlined in our medium-term management plan. We are confident that it will allow us to provide innovative POCT solutions that offer excellent performance, value for money, and convenience.

#### Comments from Ron Zwanziger, Chairman and Founder, ElecraDx, Inc.

We are thrilled to partner with TAUNS Laboratories, a trusted leader in Japan's diagnostic industry with decades of expertise and proven innovation. We have enjoyed a long-standing relationship with Tauns and Nonaka-San and are excited to further strengthen this collaboration. TAUNS's deep understanding of the Japanese healthcare market and their long-standing commitment to quality make them the ideal partner to help bring ElecraDx's next-generation POCT technology to healthcare professionals and patients in Japan. We look forward to working closely together to accelerate access to fast, accurate, and affordable diagnostic solutions.

## **2. Contents of Business Alliance**

The two companies have agreed on joint development of the ElecraDx testing platform and Tauns shall have exclusive commercialization rights in Japan.

## **3. Overview of Capital and Business Alliance Partners**

(1) Name	ElectraDx, Inc.
(2) Registered Address	838 Walker Road, Suite 21-2, Dover, Delaware, U.S.A.
(3) Title and name of representative	Veronique Ameye, CEO
(4) Business	Research, development, and commercialization of next-generation POCT and home testing focused on the field of chronic diseases
(5) Authorized Capital stock	64,376
(6) Date of establishment	November 2023
(7) Corporate site	<a href="http://www.electradx.com">www.electradx.com</a>

## **4. Future Outlook**

At present, TAUNS believes that this alliance will have a minimal impact on the business performance of TAUNS, but we will disclose any significant impact as soon as it is identified.

### **About TAUNS**

TAUNS Laboratories, Inc. is one of the major companies of infectious disease POCT in Japan. We manufacture in vitro diagnostic test kits and research reagents applying various diagnostic technologies for global consumption.

In the field of infectious disease POCT, which are our main products, we have been widely known for high-quality products and customer services by hospitals, clinics, research institutes and biotech start-ups.

For over 30 years since the company was established in 1987, under the corporate philosophy of enriching lives and providing peace of mind, we have strived to develop and improve our products.

In recent years, in addition to POCT, we have been actively developing new business areas such as contract inspection services using advanced technologies.

We will continue to conduct research and development to meet the needs of clinical testing.

For more information, please refer to the company's website 《<https://www.tauns.co.jp/en/>》.